Healthcare / BiotechnologyParis
$0.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-3.7M · quality 49.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$190
P/E
N/A
•EV/EBITDA
N/A
•ROE
-182.2%
↓Gross Margin
11.6%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+153.1%
FCF CAGR
—
FCF margin
-1004.8%
FCF / Net income
0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $366346.0 · net income $-32.9M · FCF $-3.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $366346.00 | $366346.00 | $534269.00 | $2479.00 | $22595.00 |
| Net Income | $-32.9M | $-32.9M | $-8.7M | $-3.5M | $-11.8M |
| EBITDA | $-26.1M | $-26.1M | $-4.0M | $-3.9M | $-12.3M |
| EPS | -221.36 | -221.36 | -249812.86 | -1182834.33 | -47731.06 |
| Gross Margin | 11.6% | 11.6% | 5.6% | -23192.0% | -2046.1% |
| Operating Margin | -3731.8% | -3731.8% | -2305.1% | -273345.0% | -34922.6% |
| Net Margin | -8984.5% | -8984.5% | -1636.5% | -143142.5% | -52389.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 |
| Current Ratio | 0.67 | 0.67 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.7M | $-3.7M | $-2.1M | $-4.6M | $-10.3M |
| Returns | |||||
| ROE | -182.2% | -182.2% | -17.9% | -7.1% | -27.0% |
| Valuation | |||||
| P/B | 0.00 | 0.00 | 0.01 | 0.02 | 0.23 |
| Growth & Yield | |||||
| Revenue Growth | -31.4% | -31.4% | 21451.8% | -89.0% | — |
| EPS Growth | 99.9% | 99.9% | 78.9% | -2378.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-100.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-249812.86 → -221.36
Residual
-100.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.